23andme Holding Co.

Health Care
Biotechnology: Pharmaceutical Preparations
www.23andme.com

Moat Score

Market Cap $5.09M
PE -0
Debt $NaN
Cash $137.07M
EV $NaN
FCF -$123.03M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$615.31M
EBIT	-$615.32M
ROE	-604%
ROA	-193%
FCF	-$123.03M
Equity	$101.93M
Growth Stability	1
PE	-0.01
PB	0.05
P/FCF	-0.04
P/S	0.03
Price/Cash	26.92
Net Margins	-152%
Gross Margins	47%
Op. Margins	-318%
Sales Growth YoY	-12%
Sales Growth QoQ	9%
Sales CAGR	-5%
Equity CAGR	560%
Earnings Growth YoY	-21%

Earnings Growth QoQ	-15%
Sales CAGR 5Y	-5%
Equity CAGR 5Y	560%
Earnings CAGR 3Y	-12%
Sales CAGR 3Y	-12%
Equity CAGR 3Y	-55%
Market Cap	$5.09M
Revenue	$193.26M
Assets	$318.94M
Cash	$137.07M
Shares Outstanding	1.26M
Moat Score	0%
Working Capital	35.95M
Current Ratio	1.24
Gross Profit	$89.89M
Shares Growth 3y	12%
Equity Growth QoQ	-29%
Equity Growth YoY	-84%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.

SEC Filings

Direct access to 23andme Holding Co. (ME) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31
2023
- 10-Q Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31
2022
- 10-Q Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31

Sector Comparison

How does 23andme Holding Co. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of 23andme Holding Co. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

23andme Holding Co. Discounted Cash Flow

Fully customizable DCF calculator online for 23andme Holding Co..

Years

Calculation mode

= -$1.2B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$123M	-$123M	-$123M	-$123M	-$123M	-$123M	-$123M	-$123M	-$123M	-$123M	-$123M	-$1.2B
DCF		-$112M	-$102M	-$92M	-$84M	-$76M	-$69M	-$63M	-$57M	-$52M	-$47M	-$474M
Value	-$1.2B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	03/2020	03/2021	03/2022	03/2023	03/2024	TTM
Net Margins	-82%	-75%	-80%	-104%	-304%	-152%
ROA	-	-36%	-19%	-33%	-169%	-193%
ROE	-	-4K%	-24%	-44%	-354%	-604%

Bad Net Margins (-152.1%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	03/2020	03/2021	03/2022	03/2023	03/2024	TTM
Debt over FCF	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	03/2020	03/2021	03/2022	03/2023	03/2024	CAGR 5Y
Revenue YoY growth	-	-20%	11%	10%	-27%	-5%
Earnings YoY growth	-	-27%	18%	43%	114%	-
Equity YoY growth	-	33K%	18K%	-22%	-74%	560%
FCF YoY growth	-	-69%	118%	-1%	-2%	-